ATE420881T1 - Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors - Google Patents

Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors

Info

Publication number
ATE420881T1
ATE420881T1 AT04816874T AT04816874T ATE420881T1 AT E420881 T1 ATE420881 T1 AT E420881T1 AT 04816874 T AT04816874 T AT 04816874T AT 04816874 T AT04816874 T AT 04816874T AT E420881 T1 ATE420881 T1 AT E420881T1
Authority
AT
Austria
Prior art keywords
modulators
heterocyclic compounds
serotonin receptor
condensed heterocyclic
condensed
Prior art date
Application number
AT04816874T
Other languages
German (de)
English (en)
Inventor
Nicholas Carruthers
Wenying Chai
Xiaohu Deng
Curt Dvorak
Annette Kwok
Jimmy Liang
Neelakandha Mani
Dale Rudolph
Victoria Wong
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34526458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE420881(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE420881T1 publication Critical patent/ATE420881T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04816874T 2003-09-17 2004-09-15 Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors ATE420881T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50452803P 2003-09-17 2003-09-17
US55267304P 2004-03-11 2004-03-11

Publications (1)

Publication Number Publication Date
ATE420881T1 true ATE420881T1 (de) 2009-01-15

Family

ID=34526458

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04816874T ATE420881T1 (de) 2003-09-17 2004-09-15 Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors

Country Status (29)

Country Link
US (5) US7402680B2 (cg-RX-API-DMAC7.html)
EP (1) EP1668014B1 (cg-RX-API-DMAC7.html)
JP (1) JP5069907B2 (cg-RX-API-DMAC7.html)
KR (1) KR101151653B1 (cg-RX-API-DMAC7.html)
CN (1) CN103788089A (cg-RX-API-DMAC7.html)
AR (1) AR047218A1 (cg-RX-API-DMAC7.html)
AT (1) ATE420881T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004283196B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414541B8 (cg-RX-API-DMAC7.html)
CA (1) CA2539426C (cg-RX-API-DMAC7.html)
CL (1) CL2009000943A1 (cg-RX-API-DMAC7.html)
CR (1) CR8302A (cg-RX-API-DMAC7.html)
CY (1) CY1109416T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004019118D1 (cg-RX-API-DMAC7.html)
DK (1) DK1668014T3 (cg-RX-API-DMAC7.html)
EA (2) EA010905B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066436A (cg-RX-API-DMAC7.html)
ES (1) ES2319539T3 (cg-RX-API-DMAC7.html)
IL (2) IL174283A (cg-RX-API-DMAC7.html)
IS (1) IS2756B (cg-RX-API-DMAC7.html)
MX (1) MXPA06003150A (cg-RX-API-DMAC7.html)
NI (1) NI200600094A (cg-RX-API-DMAC7.html)
NZ (1) NZ545836A (cg-RX-API-DMAC7.html)
PL (1) PL1668014T3 (cg-RX-API-DMAC7.html)
PT (1) PT1668014E (cg-RX-API-DMAC7.html)
SG (1) SG146683A1 (cg-RX-API-DMAC7.html)
SI (1) SI1668014T1 (cg-RX-API-DMAC7.html)
TW (1) TWI345565B (cg-RX-API-DMAC7.html)
WO (1) WO2005040169A2 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010905B1 (ru) * 2003-09-17 2008-12-30 Янссен Фармацевтика Н.В. Сопряжённые гетероциклические соединения
US20080161419A1 (en) * 2004-02-20 2008-07-03 Shinobu Akuzawa Prophylactic Antimigraine Agents
CN1980710B (zh) * 2004-06-30 2013-06-12 阿特西斯公司 作为5-羟色胺受体调节剂的取代的氮杂环庚烯衍生物
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP4998258B2 (ja) * 2005-02-08 2012-08-15 アステラス製薬株式会社 過敏性腸症候群の治療薬
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0513886D0 (en) * 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
NZ565334A (en) * 2005-08-04 2010-12-24 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US8076348B2 (en) 2005-08-08 2011-12-13 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
EP1981337B1 (en) * 2006-01-19 2015-09-02 Athersys, Inc. Thiophenyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
US8012957B2 (en) 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
US7915404B2 (en) 2006-05-05 2011-03-29 Janssen Pharmaceutica Nv Methods for the preparation of pyrazole-containing compounds
US20100029617A1 (en) * 2006-08-28 2010-02-04 Actelion Pharmaceuticals Ltd. 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists
WO2009058810A1 (en) * 2007-11-02 2009-05-07 Janssen Pharmaceutica N.V. Process for the preparation of substituted 2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene derivatives
US8404863B2 (en) 2008-01-03 2013-03-26 Allergan, Inc. Tetrahydroindoles having sphingosine-1-phosphate receptor activity
US8829011B2 (en) 2008-10-29 2014-09-09 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
CA2739900C (en) 2008-11-18 2016-11-08 F. Hoffmann-La Roche Ag Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
US8309578B2 (en) * 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
US8492374B2 (en) * 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
KR101911974B1 (ko) 2011-04-21 2018-10-25 바스프 에스이 신규 살충 피라졸 화합물
SG11201400277VA (en) 2011-09-14 2014-05-29 Proximagen Ltd New enzyme inhibitor compounds
WO2013156318A1 (en) 2012-04-16 2013-10-24 Basf Se Substituted pesticidal pyrazole compounds
ES2660132T3 (es) 2012-06-20 2018-03-20 Basf Se Compuestos de pirazol plaguicidas
PE20151139A1 (es) * 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirrolopirazoles como bloqueadores del canal de calcio tipo n
WO2014063942A1 (en) 2012-10-23 2014-05-01 Basf Se Substituted pesticidal pyrazole compounds
SG11201504749TA (en) 2012-12-21 2015-07-30 Abt Holding Co Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof
WO2014159067A1 (en) 2013-03-13 2014-10-02 Abt Holding Company Thienylindole azepines as serotonin 5-ht2c receptor ligands and uses thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2015055497A1 (en) 2013-10-16 2015-04-23 Basf Se Substituted pesticidal pyrazole compounds
EP3221321B1 (en) * 2014-11-21 2021-12-15 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
EP3256450B1 (en) * 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
CN105503647A (zh) * 2015-12-10 2016-04-20 苏州昊帆生物科技有限公司 环丙基肼盐酸盐的制备方法
US9951039B2 (en) * 2016-04-08 2018-04-24 The Hong Kong Polytechnic University Pyrimidines for treatment of bacterial infections
KR101917264B1 (ko) * 2016-12-22 2018-11-13 한국과학기술연구원 5-ht7 수용체 조절제로 작용하는 아제핀 유도체
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2019137995A1 (en) 2018-01-11 2019-07-18 Basf Se Novel pyridazine compounds for controlling invertebrate pests
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
EP4105206A4 (en) * 2020-01-13 2024-08-14 Aptabio Therapeutics Inc. NOVEL PYRAZOLE DERIVATIVE
PH12022552056A1 (en) 2020-02-07 2024-02-12 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
EP4665730A1 (en) 2023-02-16 2025-12-24 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197466B (de) * 1962-03-22 1965-07-29 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen
US3312716A (en) * 1964-08-11 1967-04-04 Aldrich Chem Co Inc 4-hydroxy-3-pyrrolidinemethanols
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1484140A (en) 1974-04-24 1977-08-24 Wyeth John & Brother Ltd Pyrrolopyridine derivatives
US3969355A (en) * 1974-11-01 1976-07-13 Morton-Norwich Products, Inc. 5-Aminoethyl-2,4-diphenylpyrimidine dihydrobromide
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK27383A (da) * 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4857330A (en) * 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
JPH03148265A (ja) 1989-11-01 1991-06-25 Sumitomo Chem Co Ltd ５，７―ジフェニル―４，６―ジアザインダン誘導体、その製造法およびそれを有効成分とする除草剤
US5137890A (en) * 1990-02-14 1992-08-11 Ortho Pharmaceutical Corporation 4-phenyl tetrahydropyrido(4,3-d)pyrimidines
US5053508A (en) 1990-03-09 1991-10-01 American Home Products Corporation Fused heterotricyclic imides with psychotropic activity and intermedrates thereof
US5648352A (en) 1991-09-13 1997-07-15 Merck & Co., Inc. Piperazinylcamphorsulfonyl oxytocin antagonists
FI943948L (fi) 1992-12-28 1994-08-26 Eisai Co Ltd Heterosykliset hiilihappojohdannaiset
US5843912A (en) 1994-07-06 1998-12-01 Universy Of Maryland Ring-expanded nucleosides and nucleotides
US6677310B1 (en) 1999-04-21 2004-01-13 Nabi Ring-expanded nucleosides and nucleotides
US5405848A (en) * 1993-12-22 1995-04-11 Ortho Pharmaceutical Corporation Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors
US5663178A (en) * 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
ATE271553T1 (de) 1994-04-29 2004-08-15 Pfizer Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung
CA2218143A1 (en) 1995-04-18 1996-10-24 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
EP0883613A1 (en) 1996-02-09 1998-12-16 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
TW470745B (en) * 1996-05-23 2002-01-01 Janssen Pharmaceutica Nv Hexahydro-pyrido[4,3-b]indole derivatives
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
JP2000512646A (ja) 1996-06-25 2000-09-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ７受容体アンタゴニストとしてのスルホンアミド誘導体
JP4076234B2 (ja) 1996-06-28 2008-04-16 明治製菓株式会社 テトラヒドロベンズインドール化合物
GB9700899D0 (en) 1997-01-17 1997-03-05 Smithkline Beecham Plc Novel treatment
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
WO1998040385A1 (en) 1997-03-07 1998-09-17 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
EP0905136A1 (en) * 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
US5951518A (en) 1997-10-31 1999-09-14 Teleflex, Incorporated Introducing device with flared sheath end
AU1558899A (en) 1997-11-10 1999-05-31 F. Hoffmann-La Roche Ag Isoquinoline derivatives for use against cns disorders
WO1999054303A1 (en) 1998-04-22 1999-10-28 Meiji Seika Kaisha, Ltd. Optically active tetrahydrobenzindole derivatives
ID26861A (id) 1998-05-22 2001-02-15 Lilly Co Eli Terapi gabungan untuk pengobatan depresi refaktori
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
WO2000024399A1 (en) 1998-10-23 2000-05-04 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6245785B1 (en) 1998-11-30 2001-06-12 Warner Lambert Company Dissolution of triprolidine hydrochloride
GB9828004D0 (en) 1998-12-18 1999-02-10 Smithkline Beecham Plc Use
GB9906624D0 (en) 1999-03-23 1999-05-19 Smithkline Beecham Plc Novel compounds
TR200102810T2 (tr) * 1999-04-01 2002-01-21 Pfizer Products Inc. Sorbitol dehidrojenaz inhibitörleri olarak aminopirimidinler
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6806230B1 (en) 1999-09-09 2004-10-19 Kumiai Chemical Industry Co., Ltd. Pyrimidine derivatives and herbicides containing them
AU1025601A (en) 1999-10-18 2001-04-30 Smithkline Beecham Plc Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
EP1252161A1 (en) 2000-02-04 2002-10-30 Wyeth Pyrrolo-isoquinoline and tetrahydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-ht7 receptor
US20040087798A1 (en) 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US6586469B2 (en) 2000-07-25 2003-07-01 Medpointe Healthcare Inc. Antihistaminic/antitussive compositions
MXPA03001421A (es) 2000-08-14 2004-01-26 Johnson & Johnson Pirazoles sustituidos.
CZ2003635A3 (cs) * 2000-09-06 2004-12-15 Ortho Mcneil Pharmaceutical, Inc. Substituovaný pyrazol a jeho použití
US20040267010A1 (en) 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
NZ526741A (en) * 2001-02-21 2004-04-30 Janssen Pharmaceutica Nv Isoxazoline derivatives as anti-depressants
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
US6559174B2 (en) 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
US6806380B2 (en) * 2001-10-02 2004-10-19 Lexicon Pharmaceuticals, Inc. Modified safe and efficient process for the environmentally friendly synthesis of imidoesters
BR0213562A (pt) * 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
US20030199544A1 (en) 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
US20030199542A1 (en) 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
HRP20020452A2 (en) 2002-05-23 2004-02-29 Pliva D D 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof
JP2005528443A (ja) * 2002-05-30 2005-09-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋキナーゼおよびｃｄｋ２プロテインキナーゼのインヒビター
KR20050012284A (ko) * 2002-06-20 2005-01-31 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 저해제가 사용되는 병용 치료법
AU2003244632A1 (en) 2002-07-25 2004-02-25 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20060135508A1 (en) 2002-07-25 2006-06-22 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JPWO2004011467A1 (ja) 2002-07-29 2005-12-15 北興化学工業株式会社 トリアゾロピリミジン誘導体および農園芸用殺菌剤
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US8012602B2 (en) 2002-10-30 2011-09-06 Basf Se Electroluminescent device
WO2004067703A2 (en) * 2003-01-31 2004-08-12 Pfizer Products Inc. 5ht7 antagonists and inverse agonists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
GB0316128D0 (en) 2003-07-10 2003-08-13 Univ Aston Novel sulfonamide compounds
JP4679517B2 (ja) 2003-07-23 2011-04-27 エグゼリクシス， インコーポレイテッド 薬剤としてのアゼピン誘導体
EA010905B1 (ru) * 2003-09-17 2008-12-30 Янссен Фармацевтика Н.В. Сопряжённые гетероциклические соединения
JP2007506787A (ja) 2003-09-23 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとしてのピラゾロピロール誘導体
WO2005030132A2 (en) 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
JP2007513896A (ja) 2003-12-15 2007-05-31 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20090227562A1 (en) 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
US20060037652A1 (en) 2004-08-23 2006-02-23 Ranco Incorporated Of Delaware Reversing valve assembly with improved pilot valve mounting structure
ATE496892T1 (de) * 2004-12-17 2011-02-15 Janssen Pharmaceutica Nv Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
JP2008546711A (ja) * 2005-06-17 2008-12-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｎｓ障害の処置のためのヘキサヒドロ−ピロロ−イソキノリン化合物
PL1899334T3 (pl) * 2005-06-17 2009-04-30 Janssen Pharmaceutica Nv Związki naftyrydynowe
NZ565334A (en) 2005-08-04 2010-12-24 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US7795262B2 (en) * 2006-03-10 2010-09-14 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
US7915404B2 (en) * 2006-05-05 2011-03-29 Janssen Pharmaceutica Nv Methods for the preparation of pyrazole-containing compounds
WO2008002820A2 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
US20080045508A1 (en) * 2006-06-29 2008-02-21 Brett Allison Substituted aminomethyl benzamide compounds
US7767666B2 (en) * 2006-06-29 2010-08-03 Janssen Pharmaceutica Nv Butyl and butynyl benzyl amine compounds
WO2008064036A1 (en) * 2006-11-16 2008-05-29 Janssen Pharmaceutica N.V. Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators

Also Published As

Publication number Publication date
ECSP066436A (es) 2006-09-18
BRPI0414541A (pt) 2006-11-07
US20110040088A1 (en) 2011-02-17
US7402680B2 (en) 2008-07-22
AU2004283196B2 (en) 2011-08-25
IS2756B (is) 2011-10-15
IL174283A0 (en) 2006-08-01
KR101151653B1 (ko) 2012-06-28
JP2007505908A (ja) 2007-03-15
EA200600433A1 (ru) 2006-08-25
TW200521123A (en) 2005-07-01
ES2319539T3 (es) 2009-05-08
IL209082A0 (en) 2011-01-31
TWI345565B (en) 2011-07-21
SI1668014T1 (sl) 2009-06-30
BRPI0414541B1 (pt) 2019-02-26
NZ545836A (en) 2009-09-25
BRPI0414541A8 (pt) 2019-01-02
EP1668014B1 (en) 2009-01-14
US8618288B2 (en) 2013-12-31
IL174283A (en) 2012-06-28
SG146683A1 (en) 2008-10-30
IS8348A (is) 2006-03-09
WO2005040169A2 (en) 2005-05-06
US20080103132A1 (en) 2008-05-01
HK1118550A1 (en) 2009-02-13
AR047218A1 (es) 2006-01-11
CN103788089A (zh) 2014-05-14
US20090270370A1 (en) 2009-10-29
PL1668014T3 (pl) 2009-06-30
US20100016281A1 (en) 2010-01-21
CL2009000943A1 (es) 2009-08-21
CY1109416T1 (el) 2014-08-13
KR20070023633A (ko) 2007-02-28
EA200801812A1 (ru) 2009-06-30
US7897771B2 (en) 2011-03-01
PT1668014E (pt) 2009-03-17
CA2539426A1 (en) 2005-05-06
DK1668014T3 (da) 2009-04-20
NI200600094A (es) 2014-02-25
MXPA06003150A (es) 2006-08-31
DE602004019118D1 (de) 2009-03-05
BRPI0414541B8 (pt) 2021-05-25
JP5069907B2 (ja) 2012-11-07
US20050119295A1 (en) 2005-06-02
US7579470B2 (en) 2009-08-25
EA010905B1 (ru) 2008-12-30
CA2539426C (en) 2012-07-10
AU2004283196A1 (en) 2005-05-06
EP1668014A2 (en) 2006-06-14
WO2005040169A3 (en) 2006-03-30
CR8302A (es) 2008-09-10

Similar Documents

Publication Publication Date Title
ATE420881T1 (de) Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
ATE516274T1 (de) Neue verbindungen als modulatoren des opioidrezeptors
ATE451364T1 (de) Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
EP1874736A4 (en) FUSIONED HETEROCYCLIC COMPOUNDS
DK1448523T3 (da) Heterocycliske forbindelser samt metoder til anvendelse deraf
DE602004024045D1 (de) Zyklische derivate als modulatoren der chemokinrezeptoraktivität
DE602005015732D1 (de) Heterozyklische antivirale verbindungen
ATE434618T1 (de) Spirozyklische verbindungen als hdac-hemmer
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
ATE463481T1 (de) Cyclopropylamine als modulatoren des histamin-h3- rezeptors
EP1689389A4 (en) INDOLE COMPOUNDS
EP1717225A4 (en) BICYCLIC AMIDE DERIVATIVES
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ATE495167T1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE512953T1 (de) Heterocyclische verbindungen
AU2003256922A8 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
ATE399777T1 (de) Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
IS8470A (is) Notkun lífrænna efnasambanda
ATE321764T1 (de) Tetracyclische heteroverbindungen als modulatoren des östrogenrezeptors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1668014

Country of ref document: EP